Dow Jones
38.526,66 +286,68 (+0,75%) Nasdaq
15.728,15 +276,84 (+1,79%) Nikkei 225
37.552,16 +113,55 (+0,30%) EUR/USD
1,0709 +0,0052 (+0,49%) Bitcoin EUR
62.248,84 +183,87 (+0,30%) CMC Crypto 200
1.437,02 +22,26 (+1,57%)
Kyowa Kirin Co Ltd (KY4.DU)
| Chiusura precedente | 15,80 |
| Aperto | 15,80 |
| Denaro | 15,70 x 0 |
| Lettera | 16,50 x 0 |
| Min-Max giorno | 15,80 - 15,80 |
| Intervallo di 52 settimane | 13,90 - 20,40 |
| Volume | |
| Media Volume | 0 |
| Capitalizzazione | N/D |
| Beta (5 anni mensile) | N/D |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | N/D |
| Prossima data utili | N/D |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | N/D |
GlobeNewswireKyowa Kirin to Acquire Orchard Therapeutics
-Orchard Therapeutics is a global gene therapy leader with experience successfully developing and commercializing medicines for rare diseases--Acquisition enriches Kyowa Kirin’s portfolio, enables the development of numerous promising candidates with a clinically differentiated platform, and helps resource the ongoing and future launches of Libmeldy® (atidarsagene autotemcel)--Acquisition price of $16.00 per ADS in cash plus an additional contingent value right of $1.00 per ADS, representing a t
GlobeNewswireTenapanor for Hyperphosphatemia Approved in Japan
Approval announced by Kyowa Kirin, Ardelyx Collaboration Partner Ardelyx to receive $30 million from Kyowa Kirin in milestone and license amendment payments and $5 million from HealthCare Royalty Partners under a Financing Agreement WALTHAM, Mass., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced
